Advertisement
Australia markets closed

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • AUD/USD

    0.6498
    +0.0009 (+0.15%)
     

  • OIL

    82.88
    -0.48 (-0.58%)
     

  • GOLD

    2,332.50
    -9.60 (-0.41%)
     

  • Bitcoin AUD

    101,438.32
    -918.78 (-0.90%)
     

  • CMC Crypto 200

    1,430.32
    +6.22 (+0.44%)
     

  • AUD/EUR

    0.6075
    +0.0018 (+0.30%)
     

  • AUD/NZD

    1.0950
    +0.0020 (+0.18%)
     

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NASDAQ

    17,601.24
    +129.77 (+0.74%)
     

  • FTSE

    8,068.41
    +23.60 (+0.29%)
     

  • Dow Jones

    38,476.53
    -27.16 (-0.07%)
     

  • DAX

    18,147.53
    +9.88 (+0.05%)
     

  • Hang Seng

    17,201.27
    +372.34 (+2.21%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

Prothena to Report First Quarter 2023 Financial Results on May 4

Business Wire
·1-min read

DUBLIN, April 27, 2023--(BUSINESS WIRE)--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its first quarter 2023 financial results on Thursday, May 4, 2023 after the close of the U.S. financial markets.

Consistent with past practice, the Company will not be conducting a conference call in conjunction with this financial results release on May 4.

About Prothena

Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a number of other neurodegenerative diseases. For more information, please visit the Company’s website at www.prothena.com and follow the Company on Twitter @ProthenaCorp.

ADVERTISEMENT

View source version on businesswire.com: https://www.businesswire.com/news/home/20230427005633/en/

Contacts

Investors
IR@prothena.com

Media
Michael Bachner, Senior Director, Corporate Communications
609-664-7308, michael.bachner@prothena.com